Pediatrics

The agency previously granted a priority review for the supplemental new drug application and also approved the drug in 2015 to treat adults.

GeneSight Mental Health Monitor finds that many struggle to know the difference between teenage behavior and a mental health challenge.

Study results show that these regimens increased the chances of treatment success among individuals aged 3 to 18 years compared to standard therapeutics.

Study results show that fetal cognitive development in the assessed areas was age-appropriate and there was no indication of infection.

Lomecel-B (Longeveron) is an investigational allogeneic, bone marrow-derived medicinal signaling cell medication that is being evaluated in a phase 2 trial.

In a report, the World Health Organization and a partner ask developers, funders, and investigators to accelerate developing a vaccination.

Study shows that about half the pediatric cases were symptomatic compared with 88% for individuals aged 18 years and older.

Linda Mendonça, DNP, RN, PHNA-BC, president of the National Association of School Nurses, discusses a new poll released by the COVID-19 Vaccine Education and Equity Project and the National Association of School Nurses about parents’ plans to vaccinate their school-aged children.

The results of a review by Murdoch Children’s Research Institute finds that pediatric patients who are vaccinated get protection from the long-term effects of the disease.

Investigators observed improvements in inflammation of the cornea and ocular itching among patients receiving Verkazia in both trials.

The condition is not preventable, but there are steps that can be taken to reduce LDL-C levels in children.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses the value of the pharmacist in administering COVID-19 vaccines to adolescents and children.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses how health care professionals should approach discussing issues around vaccine hesitancy with parents.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses his decision to enroll his twin daughters in the Moderna COVID-19 vaccine trial.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, on the future of COVID-19 disease and vaccines for adolescents and children.

Hannah Fish, PharmD, associate director of strategic initiatives at NCPA, discusses the role of the pharmacist in vaccinating children ages 12 and older against COVID-19 following the FDA updating the Pfizer COVID-19 vaccine EUA.

Hannah Fish, PharmD, National Community Pharmacists Association associate director of Strategic Initiatives, discusses the next phase of the COVID-19 vaccination rollout following the FDA expanding the Pfizer-BioNTech COVID-19 vaccine EUA to include children ages 12 and older.

This data could offer additional insights into how the pandemic may be impacting the nation's children, according to the study authors.

The FDA has expanded its approval of short ragweed pollen allergen extract (Ragwitek; ALK) to include treatment for children and adolescents, starting at age 5 years, with short ragweed pollen-induced allergic rhinitis.

Despite significant decreases in 2020, a large number of adolescents less than 18 years of age continue to use e-cigarettes, with considerable adverse health effects, according to a presentation at the 2021 National Association of Pediatric Nurse Practitioners (NAPNAP) conference.

First approved by the FDA in 1989 for 2 rare eye muscle disorders, onabotulinumtoxinA (Botox; Allergan) was the world’s first approved botulinum toxin type A treatment.

Push continues for more access to EpiPens, but it is important to protect health care providers who administer the treatment.

Data show that children with cancer who are experiencing neighborhood poverty and rely on public health insurance have an increased risk of death with stem cell treatment.

Clinicians often reserve vigilance with drug-related issues for critically ill patients or older populations, while mistaking the resilience of childhood as a protective barrier.

A table showing recommended immunization schedules for child and adolescent patients.